License agreement on NK cell therapy technology

This agreement will bring significant benefit to the targeted treatment of patients suffering from cancer.  The agreement not only opens up new opportunities for the development of NK-antibody combination therapies but also has a significant positive impact on the production time of Glycostem’s lead product oNKord® and its second (CAR-NK) and third (TCR-NK) generation therapies – viveNK™. Read the whole press release here.